Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metastatic Prostate Cancer

Metastatic Prostate Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metastatic Prostate Cancer

33 trials tracked for Metastatic Prostate Cancer: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 336 citations.

33Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 21 Phase 1 2 Other / NA 3
  1. Phase 3 Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Completed · 336 cited
  2. Phase 3 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Completed · 282 cited
  3. Phase 4 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Completed · 67 cited
  4. Phase 3 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Completed
  5. Phase 3 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer Completed
  6. Phase 3 TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Completed
Show 27 more trials
  1. Phase 3 Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Completed
  2. Phase 2 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) Completed
  3. Phase 2 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Completed
  4. Phase 2 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Completed
  5. Phase 2 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Completed
  6. Phase 2 Phase II Sunitinib Prog Met AIPC Completed
  7. Phase 2 ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer Completed
  8. Phase 2 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). Completed
  9. Phase 2 Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer Completed
  10. Phase 2 Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer Completed
  11. Phase 2 COMbination of Bipolar Androgen Therapy and Nivolumab Completed
  12. Phase 2 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer Completed
  13. Phase 2 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer Completed
  14. Phase 2 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed
  15. Phase 2 Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer Completed
  16. Phase 2 Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer Completed
  17. Phase 2 Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer Completed
  18. Phase 2 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Completed
  19. Phase 2 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Completed
  20. Phase 2 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Completed
  21. Phase 2 One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ Completed
  22. Phase 2 A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Completed
  23. Phase 1 PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study Completed
  24. Phase 1 Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer Completed
  25. N/A PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Completed
  26. N/A MSG Use With 18F-DCFPyL PET/CT Imaging Completed
  27. N/A PROState Pathway Embedded Comparative Trial Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Metastatic Prostate Cancer: what the trials found

Cabazitaxel demonstrated significant improvements in radiographic progression-free survival (rPFS), progression-free survival (PFS), and overall survival (OS) compared to standard treatments 2.

Triptorelin pamoate (embonate) salt achieved a 99.5% success rate in reaching castrate levels of serum testosterone by day 29, with 100% maintenance through week 24, and resulted in a reduction of PSA by approximately 90-92% at weeks 12 and 24 5.

TAVT-45 successfully achieved castrate levels of serum testosterone (approximately 1.0 ng/dL) across multiple evaluation groups 6.

PROSTVAC-V showed no statistically significant difference in overall survival compared to other arms 4.

Recent results — preliminary, needs further review

  • I-131-1095 showed a significantly higher PSA response rate (44% vs 10%) but did not show a statistically significant difference in objective response rate or radiographic progression-free survival 9.
  • Bavdegalutamide showed a 48.9% rate of patients without PSA progression 1.

For the clinician treating this condition

  • Cabazitaxel is associated with statistically significant improvements in rPFS, PFS, and OS 2.
  • Triptorelin pamoate and TAVT-45 are effective for achieving and maintaining castrate levels of serum testosterone [5, 6].
  • PROSTVAC-V did not demonstrate a statistically significant impact on overall survival 4.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer with HR gene alterations
Oncology RCT
Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer with HR gene alterations New drug combination slows progression of metastatic prostate cancer
This interim analysis investigated the addition of talazoparib to enzalutamide for patients with metastatic androgen pathway modulation-sens…
A new drug combination significantly extends the time before prostate cancer progresses for patients with specific genetic markers.
Jul 31, 2026
Longitudinal ctDNA analysis identifies AR gene alterations and extrachromosomal DNA as features of resistance
Oncology Phase III
Longitudinal ctDNA analysis identifies AR gene alterations and extrachromosomal DNA as features of resistance Blood tests may track how prostate cancer resists treatment
This observational study of 327 patients with metastatic castration-resistant prostate cancer (mCRPC) utilized longitudinal ctDNA analysis t…
New research shows that tracking DNA in the blood can help identify specific genetic changes when prostate cancer stops responding to therap…
Jun 18, 2026